Glipizide-d₁₁is intended for use as an internal standard for the quantification of glipizide by GC- or LC-MS. Glipizide is a hypoglycemic agent.¹It inhibits ATP-sensitive potassium (K_ATP) channels in primary mouse pancreatic β cells (IC₅₀= 6.4 nM). Glipizide induces insulin release from isolated rat pancreatic tissue with an EC₅₀value of 40 nM.²Dietary administration of glipizide (5 mg/kg per day for 10 days) increases the number of insulin receptors on isolated and purified mouse liver plasma membranes.³It reduces plasma glucose and triglyceride, but not total cholesterol, levels and increases plasma insulin levels in a rat model of diabetes induced by a high-fat diet and streptozotocin when administered orally at a dose of 5 mg/kg.⁴Formulations containing glipizide have been used in the treatment of type 2 diabetes.

1.ZÜnkler, B.J., Lenzen, S., MÄnner, K., et al.Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cellsNaunyn-Schmiedebergs Arch. Pharmacol.337(2)225-230(1998) 2.Herchuelz, A., and Malaisse, W.J.Insulinotropic potency of glipizide in vitroDiabetologia309-310(1973) 3.Feinglos, M.N., and Lebovitz, H.E.Sulphonylureas increase the number of insulin receptorsNature276(5684)184-185(1978) 4.Srinivasan, K., Viswanad, B., Asrat, L., et al.Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screeningPharmacol. Res.52(4)313-320(2005)